Forvisirvat

Forvisirvat
Clinical data
Other names	SP624
Routes of; administration	Oral
Drug class	Sirtuin-6 (SIRT6) activator
Identifiers
	IUPAC name (2S,5'R)-7-chloro-3',4-dimethoxy-5'-methyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)spiro[1-benzofuran-2,4'-cyclohex-2-ene]-1',3-dione;
CAS Number	2135638-06-9;
PubChem CID	131964504;
ChemSpider	129910029;
Chemical and physical data
Formula	C19H17ClN2O6
Molar mass	404.80 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(C=C(C(=C3O2)Cl)C4=NN=C(O4)C)OC)OC;
	InChI InChI=1S/C19H17ClN2O6/c1-8-5-10(23)6-13(26-4)19(8)17(24)14-12(25-3)7-11(15(20)16(14)28-19)18-22-21-9(2)27-18/h6-8H,5H2,1-4H3/t8-,19+/m1/s1; Key:MIHSWFYCAJWPIS-YLVJLNSGSA-N;

Forvisirvat (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name SP-624) is a sirtuin-6 (SIRT6) activator which is under development for the treatment of major depressive disorder and schizophrenia.^[1]^[2]^[3]^[4]^[5] It is taken by mouth.^[1] As of January 2025, forvisirvat is in phase 2/3 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia.^[1]^[2]^[4] It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.^[1]^[2]^[5]

References

^ ^a ^b ^c ^d ^e ^f "SP 624". AdisInsight. 29 August 2024. Retrieved 23 October 2024.
^ ^a ^b ^c "Delving into the Latest Updates on SP-624 with Synapse". Synapse. 21 September 2024. Retrieved 23 October 2024.
^ Rigdon G, Prescott Y, Hall J, Abernathy K, Raskin J, Wargin W (2025). "Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults". Clinical Pharmacology in Drug Development. 14 (1): 18–25. doi:10.1002/cpdd.1488. ISSN 2160-763X. PMC 11701958. PMID 39587867.
^ ^a ^b Liu R, Li Y, Zheng Q, Ding M, Zhou H, Li X (March 2024). "Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead". Acta Pharmaceutica Sinica. B. 14 (3): 1009–1029. doi:10.1016/j.apsb.2023.10.023. PMC 10935124. PMID 38486982.
^ ^a ^b "Depression treatment shows 'robust efficacy' in women in phase 2 trial". Daily Medical News, Free CME and Clinical Guidance. 19 October 2022. Retrieved 23 October 2024.

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

[AdisInsight-1] ^ ^a ^b ^c ^d ^e ^f "SP 624". AdisInsight. 29 August 2024. Retrieved 23 October 2024.

[Synapse-2] "Delving into the Latest Updates on SP-624 with Synapse". Synapse. 21 September 2024. Retrieved 23 October 2024.

[Rigdon_2025-3] Rigdon G, Prescott Y, Hall J, Abernathy K, Raskin J, Wargin W (2025). "Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults". Clinical Pharmacology in Drug Development. 14 (1): 18–25. doi:10.1002/cpdd.1488. ISSN 2160-763X. PMC 11701958. PMID 39587867.

[Liu_2024-4] Liu R, Li Y, Zheng Q, Ding M, Zhou H, Li X (March 2024). "Epigenetic modification in liver fibrosis: Promising therapeutic direction with significant challenges ahead". Acta Pharmaceutica Sinica. B. 14 (3): 1009–1029. doi:10.1016/j.apsb.2023.10.023. PMC 10935124. PMID 38486982.

[Healio2022-5] "Depression treatment shows 'robust efficacy' in women in phase 2 trial". Daily Medical News, Free CME and Clinical Guidance. 19 October 2022. Retrieved 23 October 2024.

[1]

[2]

[3]

[4]

[5]

See also

References